Hints and tips:
Related Special Reports
...Merck’s drug, which is branded Lagevrio, raised hopes and sent shares in the company rallying last year after early data from a late-stage trial suggested it cut in half the risk of death and hospitalisation...
...Neta, another Jakarta EV show newcomer, revealed its Neta V-II, which will be priced from 200mn rupiah to 300mn rupiah, making it the least expensive model in the company’s Indonesia line-up....
...Merck’s research chief has called on the UK government to make the country more welcoming to pharma companies, ahead of the US-based drugmaker breaking ground on a £1bn research centre in London next week...
...The Cypriot government allowed stocks to be used to treat cats suffering with another coronavirus in the Mediterranean country, though the company said it was not approved for veterinary treatment and no...
...But, of course, there’s a reason why it’s widely called Shitibank; the sprawling, gormless Citi has for a v v v very long time proven adept at blithely ambling onto various rakes around the world....
...Merck’s drug raised fresh hopes and sent shares in the company rallying late last year after early data from a late-stage trial suggested that it cut in half the risk of death and hospitalisation....
...The new rules give the federal government the power to negotiate lower prices for some of the most expensive prescription drugs produced by Pfizer, Merck and other pharma companies purchased by Medicare,...
...Merck’s lawsuit is the first by a major drug company, but analysts predict others are likely to follow its lead and sue the government ahead of the full implementation of the drug price negotiation elements...
...Key economic and company reports Here is a more complete list of what to expect in terms of company reports and economic data this week....
...Yet Merck recorded sales worth more than $6bn between 2021 and 2022, and the figure does not include sales in poorer markets where licensed companies make generic versions of the drug....
...Yet the company’s monoclonal antibody treatment for inflammatory bowel disease has yet to be fully approved....
...Its companies have combined annual revenues of $75bn and 115,000 employees....
...Merck said the deal would strengthen the company’s position in the fast-growing field of immunology, where there is significant unmet patient need....
...the crisp company....
...“We are encouraged by these findings from Panoramic,” said Merck, which is known as MSD outside North America....
...Implementing the proposals could undermine the company’s core business model, said Merck in response to a proposal made by The Capuchin Franciscan Province of St. Joseph....
...Merck was in talks last summer to acquire Seagen for about $200 a share, or $40bn. But negotiations ended after the two failed to agree on price....
...Dean Li, president of Merck Research Laboratories, said the positive trial findings represented an important milestone in the company’s collaboration with Moderna....
...Merck had been in talks to acquire Seagen last summer, offering about $200 a share, according to people familiar with the matter....
...Campaigners are supported by more than 400 senior pharma and biotech executives at companies, including Pfizer and Merck, who have spoken out against a preliminary injunction against abortion pill mifepristone...
...Merck’s Keytruda now tackles 18 tumour types and is set to be the world’s top-selling medicine next year, according to Evaluate Vantage....
...Merck, Bristol Myers Squibb and Amgen have all used these aggressive tactics to protect blockbuster drugs from competition, said O’Reilly....
...Drugmaker Merck has defended the company’s approach to tax after a US congressional committee accused it of exploiting loopholes to avoid paying billions of dollars and blocking an inquiry into its practices...
...On paper, Merck’s interest in buying the cancer biotechnology company SeaGen for about $40bn makes plenty of sense. The US drugmaker is flush with cash — to the tune of $8.6bn at the end of March....
...“Pfizer is very good at selling but historically not renowned as having the R&D engine of a Merck or Lilly....
International Edition